MedPage Today July 30, 2024
— In randomized study, guided site-specific therapy improved PFS versus empirical chemotherapy
Site-specific therapy guided by gene-expressing profiling (GEP) could improve outcomes for patients with previously untreated cancers of unknown primary (CUP), Chinese researchers suggested.
In their single-center randomized trial of patients with unfavorable CUP, GEP-guided site-specific therapy significantly improved progression-free survival (PFS) compared with standard empirical chemotherapy (9.6 vs 6.6 months, respectively; HR 0.68, 95% CI 0.49-0.93, P=0.017), reported Xichun Hu, MD, PhD, of the Fudan University Shanghai Cancer Center, and colleagues.
Overall survival favored the site-specific therapy arm, but the difference was not statistically significant (28.2 vs 19 months; HR 0.74, 95% CI 0.52-1.06, P=0.098), according to findings published in Lancet Oncology.
“Our trial is the first randomized...
Today's Sponsors
Today's Sponsor